BR0308928A - Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular - Google Patents

Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular

Info

Publication number
BR0308928A
BR0308928A BR0308928-2A BR0308928A BR0308928A BR 0308928 A BR0308928 A BR 0308928A BR 0308928 A BR0308928 A BR 0308928A BR 0308928 A BR0308928 A BR 0308928A
Authority
BR
Brazil
Prior art keywords
cardiovascular
botulinum toxin
treatment
composition
well
Prior art date
Application number
BR0308928-2A
Other languages
English (en)
Inventor
Gregory F Brooks
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28453838&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0308928(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR0308928A publication Critical patent/BR0308928A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"USO DE TOXINA BOTULìNICA PARA O TRATAMENTO DE DOENçAS CARDIOVASCULARES, BEM COMO COMPOSIçãO PARA USO EM UM PROCEDIMENTO CARDIOVASCULAR". A presente invenção refere-se a métodos de tratamento de doenças cardiovasculares em um mamífero. Os métodos incluem uma etapa de administração de uma quantidade eficaz de uma toxina botulínica diretamente a um vaso sang³íneo de um mamífero, tratando por esse meio uma doença cardiovascular.
BR0308928-2A 2002-04-01 2003-03-24 Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular BR0308928A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/114,740 US6767544B2 (en) 2002-04-01 2002-04-01 Methods for treating cardiovascular diseases with botulinum toxin
PCT/US2003/009157 WO2003084567A1 (en) 2002-04-01 2003-03-24 Use of botulinum toxin for treating cardiovasular diseases

Publications (1)

Publication Number Publication Date
BR0308928A true BR0308928A (pt) 2005-01-04

Family

ID=28453838

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308928-2A BR0308928A (pt) 2002-04-01 2003-03-24 Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular

Country Status (13)

Country Link
US (4) US6767544B2 (pt)
EP (1) EP1490097B2 (pt)
JP (3) JP2005521735A (pt)
KR (1) KR20040105818A (pt)
AT (1) ATE355852T1 (pt)
AU (1) AU2003220511C1 (pt)
BR (1) BR0308928A (pt)
CA (1) CA2480505A1 (pt)
DE (1) DE60312309T3 (pt)
ES (1) ES2281636T5 (pt)
HK (1) HK1070575A1 (pt)
MX (1) MXPA04009410A (pt)
WO (1) WO2003084567A1 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302875B1 (en) 1996-10-11 2001-10-16 Transvascular, Inc. Catheters and related devices for forming passageways between blood vessels or other anatomical structures
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
WO2003059192A2 (en) * 2001-12-21 2003-07-24 The Trustees Of Columbia University In The City Of New York C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
AU2003259246A1 (en) * 2002-07-29 2004-02-16 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US8073538B2 (en) 2003-11-13 2011-12-06 Cardio Polymers, Inc. Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
US7906124B2 (en) * 2004-09-18 2011-03-15 Asthmatx, Inc. Inactivation of smooth muscle tissue
GB2419817A (en) * 2004-10-29 2006-05-10 Ipsen Ltd Treatment of cardiac fibrillation disorders
CN101076290B (zh) 2004-12-09 2011-11-23 铸造品股份有限公司 主动脉瓣修复
US9833618B2 (en) * 2005-02-04 2017-12-05 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
CA2601577A1 (en) 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
WO2008036060A2 (en) 2005-04-05 2008-03-27 Allergan, Inc. Clostridial toxin activity assays
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
WO2007014003A2 (en) 2005-07-22 2007-02-01 The Foundry Inc. Systems and methods for delivery of a therapeutic agent
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US20070237802A1 (en) * 2006-04-11 2007-10-11 Medtronic Vascular, Inc. Inhibition of Calcification on an Endovascular Device
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
AU2009244058B2 (en) 2008-05-09 2015-07-02 Nuvaira, Inc Systems, assemblies, and methods for treating a bronchial tree
AU2010221435B2 (en) 2009-03-06 2014-06-19 Allergan, Inc. Clostridial toxin to improve ejaculate
US9125907B2 (en) * 2009-09-30 2015-09-08 Christopher Shaari Use of botulinum neurotoxin to treat substance addictions
EP2493408B1 (en) 2009-10-27 2015-06-24 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
AU2010319477A1 (en) 2009-11-11 2012-05-24 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
WO2011137234A1 (en) * 2010-04-30 2011-11-03 Boston Scientific Scimed, Inc. Therapeutic agent delivery device for delivery of a neurotoxin
WO2012112434A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
JP5759615B2 (ja) 2011-04-08 2015-08-05 コヴィディエン リミテッド パートナーシップ 腎交感神経の除神経およびイオン導入薬物送達のためのイオン導入カテーテルシステムならびに方法
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
CA2961217A1 (en) * 2014-09-12 2016-03-17 Gary E. Borodic Longevity enhancement induced by repetitive injections of botulinum toxin (centurion effect)
PL3242884T3 (pl) 2015-01-09 2021-08-16 Ipsen Bioinnovation Limited Kationowe neurotoksyny
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
EP3519430A1 (en) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybrid neurotoxins
US11116561B2 (en) 2018-01-24 2021-09-14 Medtronic Ardian Luxembourg S.A.R.L. Devices, agents, and associated methods for selective modulation of renal nerves
EP3758611A1 (en) 2018-02-26 2021-01-06 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5092841A (en) 1990-05-17 1992-03-03 Wayne State University Method for treating an arterial wall injured during angioplasty
AU4282793A (en) † 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
JP2617407B2 (ja) 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤
US6121296A (en) * 1992-11-04 2000-09-19 Albert Einstein College Of Medicine Of Yeshiva University Transition-state inhibitors for nucleoside hydrolase and transferase reactions
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5989280A (en) 1993-10-22 1999-11-23 Scimed Lifesystems, Inc Stent delivery apparatus and method
AU688452B2 (en) * 1993-12-28 1998-03-12 Allergan, Inc. Botulinum toxins for treating various disorders and associated pain
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ATE292977T1 (de) * 1994-05-09 2005-04-15 William J Binder Präsynaptische neurotoxine gegen migränekopfschmerzen
US5626562A (en) 1994-11-28 1997-05-06 Devices For Vascular Intervention Drug delivery catheter
US6102904A (en) * 1995-07-10 2000-08-15 Interventional Technologies, Inc. Device for injecting fluid into a wall of a blood vessel
US6261318B1 (en) 1995-07-25 2001-07-17 Medstent Inc. Expandable stent
US5851786A (en) * 1995-09-27 1998-12-22 National Jewish Center For Immunology And Respiratory Medicine Product and process to regulate actin polymerization
CA2192520A1 (en) 1996-03-05 1997-09-05 Ian M. Penn Expandable stent and method for delivery of same
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US6238872B1 (en) * 1997-04-01 2001-05-29 S.E.T.-Smart Endolumenal Technologies Ltd. Targeted therapy to a biomedical device
US6344055B1 (en) 1997-05-14 2002-02-05 Novo Rps Ulc Method for production of an expandable stent
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
WO1999023977A1 (en) 1997-11-07 1999-05-20 Expandable Grafts Partnership Intravascular stent and method for manufacturing an intravascular stent
CA2338093C (en) 1998-07-20 2010-11-30 Shousun C. Szu Vaccines against escherichia coli o157 infection
US6196230B1 (en) 1998-09-10 2001-03-06 Percardia, Inc. Stent delivery system and method of use
US6293959B1 (en) 1998-11-16 2001-09-25 Cordis Corporation Balloon catheter and stent delivery system having enhanced stent retention and method
US6270521B1 (en) 1999-05-21 2001-08-07 Cordis Corporation Stent delivery catheter system for primary stenting
US6241758B1 (en) 1999-05-28 2001-06-05 Advanced Cardiovascular Systems, Inc. Self-expanding stent delivery system and method of use
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6977080B1 (en) 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6239118B1 (en) 1999-10-05 2001-05-29 Richard A. Schatz Method for preventing restenosis using a substituted adenine derivative
US6264671B1 (en) 1999-11-15 2001-07-24 Advanced Cardiovascular Systems, Inc. Stent delivery catheter and method of use
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6306162B1 (en) 1999-12-15 2001-10-23 Advanced Cardiovascular Systems, Inc. Stent delivery system utilizing novel balloon for obtaining variable post-deployment stent characteristics
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
AU2002218927B2 (en) 2001-01-04 2007-08-30 The University Of British Columbia Enterohemorrhagic Escherichia coli vaccine
US20020099356A1 (en) * 2001-01-19 2002-07-25 Unger Evan C. Transmembrane transport apparatus and method

Also Published As

Publication number Publication date
EP1490097A1 (en) 2004-12-29
KR20040105818A (ko) 2004-12-16
JP2005521735A (ja) 2005-07-21
ES2281636T3 (es) 2007-10-01
DE60312309D1 (de) 2007-04-19
US20040223975A1 (en) 2004-11-11
US7494654B2 (en) 2009-02-24
HK1070575A1 (en) 2005-06-24
DE60312309T2 (de) 2007-11-08
CA2480505A1 (en) 2003-10-16
EP1490097B1 (en) 2007-03-07
AU2003220511A1 (en) 2003-10-20
US7048927B2 (en) 2006-05-23
JP2013053167A (ja) 2013-03-21
US20030185860A1 (en) 2003-10-02
US20040142005A1 (en) 2004-07-22
MXPA04009410A (es) 2005-01-25
US6767544B2 (en) 2004-07-27
EP1490097B2 (en) 2010-08-18
JP2009102440A (ja) 2009-05-14
US7223399B2 (en) 2007-05-29
DE60312309T3 (de) 2011-02-24
WO2003084567A1 (en) 2003-10-16
ATE355852T1 (de) 2007-03-15
ES2281636T5 (es) 2010-12-17
AU2003220511C1 (en) 2008-03-06
AU2003220511B2 (en) 2006-11-16
US20060127417A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
BRPI0408476A (pt) métodos para melhorar a qualidade da pele
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA200901555A1 (ru) Композиция местного применения по уходу за кожей и способ лечения
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
EA200802213A1 (ru) Способы лечения заболеваний крови
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DK1797053T3 (da) Phenothiazinium-forbindelse til sårheling
EA200401525A1 (ru) Способы лечения гепатита (варианты )
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
EA200971053A1 (ru) Способы лечения кожных язв
CY1112397T1 (el) Συνδυασμενη θεραπεια για την αντιμετωπιση του καρκινου
EA200701995A1 (ru) Способы уменьшения кальцификации
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
EA200401366A1 (ru) Способы лечения некротизирующего энтероколита
PL1715890T3 (pl) CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową
CY1116938T1 (el) Αναπληρωτικη θεραπεια της ασθενειας huntington και αλλων ασθενειων πολυγλουταμiνης
HK1205677A1 (en) Mesenchymal stem cells and uses therefor
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2307 DE 24/03/2015.